Join our daily newsletter At The Bell to receive exclusive market insights
- Little Green Pharma (LGP) is appointed as the primary manufacturer of CBD oil for the third consecutive year for an extended national trial testing medicinal cannabis in France
- LGP’s 1:20 THC:CBD oil received approval for the trial extension, and 85 per cent of the 3000 trial participants have started their trial with either this or LGP’s CBD 50 oil
- LGP’s total supply obligation for the oil in the trial is limited to around 11,000 units, and the company has also submitted a bid to supply its CBD50 oil product for the trial extension
- LGP sees this appointment as a “significant first-mover advantage” in the French market, with an opportunity to capitalise on one of the largest potential medicinal cannabis markets in Europe
- LGP shares are up 2.8 per cent and trading at 18 cents at 1:48 pm AEST
Medicinal cannabis company Little Green Pharma (LGP) has been appointed as the primary manufacturer of CBD oil for the third consecutive year for a national trial testing medicinal cannabis in France.
The French government launched the trial in October 2020 to test medicinal cannabis on patients with severe illnesses such as drug-resistant epilepsy and was extended until March 2024 due to its success.
LGP’s 1:20 THC:CBD oil received approval for the trial extension, and 85 per cent of the 3000 trial participants have started their trial with either this or LGP’s CBD 50 oil.
The company’s total supply obligation for the oil in the trial is limited to around 11,000 units and LGP has now also separately submitted a bid to supply its CBD50 oil product for the trial extension.
According to LGP, this appointment gives it a “significant first-mover advantage” in the French market and provides “unique insight and influence” over the development of future medicinal cannabis statutory framework in France.
LGP reported its continued participation in the trial is consistent with its long-term growth strategy to capitalise on one of the largest potential medicinal cannabis markets in Europe.
The company’s partners in the trial are Intsel Chimos, a French pharmaceutical company, and Centre Lab, a pharmaceutical manufacturer who works closely with Intsel Chimos in France.
LGP will manufacture and supply its medicines to France while Intsel Chimos and Centre Lab will undertake batch-release, distribution, medical information, and pharmacovigilance obligations for the trial.
The partnership will also split the manufacturing costs of the extended trial product equally between them.
LGP reported the trial has already shown consistently beneficial clinical outcomes over its first two years, with 91 per cent of the current 1453 patients showing positive results.
The trial study will represent one of the largest European data collections on cannabis, with the success of the trial already generating calls by patient associations for the legalisation of medicinal cannabis as soon as possible.
LGP shares were up 2.8 per cent and trading at 18 cents at 1:48 pm AEST.
